Deriva

Quick links to important sections

Deriva

Treatment option: Zits, Blackheads, Acne Vulgaris

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Deriva

Property Description
Active Ingredient Adapalene (INN)
Pharmacological Class Topical Retinoid
Origin / Type Synthetic Compound (Naphthoic acid derivative)
Dosage Forms Cream and Gel
Route of Administration Topical (Dermatological)

Classification and Purpose as a Topical Retinoid

Deriva is a pharmaceutical preparation containing the active ingredient Adapalene, which is fundamentally classified as a third-generation synthetic retinoid. This classification is clinically recognized for its highly targeted action on skin cell receptors. Adapalene belongs to the class of retinoid-like compounds that work by preventing the formation of blemishes beneath the skin's surface.

Adapalene is chemically a unique Naphthoic acid derivative whose main purpose is defined by its role as a powerful comedolytic agent. This signifies that its primary function is to break down existing clogs and inhibit the formation of new follicular blockages. As a pharmacological agent in managing skin conditions, Adapalene acts by normalizing the growth and shedding of skin cells. This substance modulates cellular differentiation, representing a key advancement over first-generation retinoids.

Composition and Available Topical Forms

This medicine is a single product whose only active component is Adapalene, delivered via a suitable base for topical application. Deriva is manufactured in two primary dosage forms: a cream and a gel.

The distinction between these two forms lies in the base: the cream utilizes an aqueous base, while the gel uses a hydroalcoholic base. This choice provides flexibility, allowing the topical preparation to be matched to patient preference or skin type. Both presentations deliver the synthetic compound Adapalene locally, ensuring the active ingredient can target the affected skin area effectively. This focus on topical delivery underlines the medicine's identity as a specialized dermatological preparation.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Deriva?

Possible Side Effects and Safety Information

The safety profile of this topical retinoid, containing Adapalene, is characterized primarily by local cutaneous reactions that are transient and generally lessen over time. Regulatory documents classify these effects according to frequency and body system.


Frequency-Classified Adverse Reactions

The majority of documented effects fall into the common category, affecting the Skin and subcutaneous tissue disorders system:

  • Common (1/100 to 1/10): Erythema (redness), dryness, scaling (peeling), skin burning sensation, and skin irritation.
  • Uncommon (1/1,000 to 1/100): Pruritus (itching), rash, and sunburn.

These local signs and symptoms are most likely to occur during the first two to four weeks of therapy and are documented to usually lessen with continued use of the medicine.


Serious Adverse Reactions and Key Constraints

Serious adverse reactions, reported through post-marketing surveillance, are rare and include anaphylactic reaction, angioedema (swelling of the face or eyelids), and application site burn. These are classified as Not Known frequency.

The regulatory label outlines several non-dosing constraints:

  • Pregnancy: The medicine is contraindicated during pregnancy.
  • Photosensitivity: Exposure to sunlight and UV light irradiation should be minimized during use, and the product should not be applied to sunburned skin.
  • Contraindications: Use is restricted in cases of documented hypersensitivity to Adapalene or any excipients.

Safety is not established for pediatric patients below 12 years of age or for patients over 65 years of age.

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose is a serious medical event that requires immediate attention. For Deriva products (which contain a retinoid active ingredient), the risk profile depends on the formulation.

Topical Products (Gel/Cream): Accidental ingestion of the topical gel or cream may occur, which warrants immediate medical help. Symptoms of overdose are generally unlikely with external use due to minimal systemic absorption, but applying excessive amounts may lead to marked local irritation, redness, scaling, or discomfort. If extra quantities are applied, gently wipe off the excess product. If the topical product is swallowed, you must call a Poison Control Center or local emergency services immediately. If the individual is unconscious or not breathing, call 911 or your local emergency number.

Oral Capsule Products: Overdosing on the oral capsule formulation (containing a retinoid derivative) can lead to systemic toxic signs. Reported overdose manifestations include increased intracranial pressure, vomiting, dizziness, headache, loss of balance, stomach pain, or swollen and cracked lips. When signs of overdose are noted, treatment often involves discontinuing the product, as the toxic signs commonly resolve spontaneously. However, severe manifestations like increased intracranial pressure may require specific interventions, such as treatment with mannitol or hyperventilation. If you suspect an overdose, seek urgent medical attention immediately.

Therapeutic Uses of Deriva

What Deriva Treats: Main Uses and Benefits

This preparation is commonly used for the symptomatic management of Acne Vulgaris, a condition the medication is approved to treat in adolescents and adults. The preparation is applied in addressing a wide range of physical manifestations, including both non-inflammatory lesions like blackheads and whiteheads, and visible inflammatory lesions such as papules and pustules. The medication assists with the symptomatic management of existing blemishes and may contribute to easing the visible signs of irritation.

The therapeutic approach is relevant for sustained management, often playing a role as a foundational or maintenance therapy to help manage the recurrence of acne. It is applied to help manage the formation of new follicular blockages, offering the key benefit of supporting the long-term goal of managing skin stability and provides support that helps ease the symptom load of persistent acne. This application is generally relevant in patients who present with mild to moderate levels of acne severity.

“This approach is commonly used when additional management of discomfort and recurrent breakouts is required.”

This broad application provides supportive relief for a wide range of typical symptomatic experiences, and may assist with maintaining functional stability and general well-being during symptomatic phases.


Quick Fact: Supports Management of Comedonal and Inflammatory Lesions

Regulatory References

  1. NIH MedlinePlus overview of Adapalene

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Deriva — Official Regulatory Information

Deriva (Adapalene or Adapalene/Benzoyl Peroxide) is a topical retinoid primarily intended for specific populations as defined in government regulatory documents (e.g., FDA Prescribing Information, EMA SmPC).


Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed: Patients 12 years of age and older (or 9 years and older for some combination products).
Populations for whom use is contraindicated: Individuals with known hypersensitivity to adapalene or any excipients; Pregnant women and women planning a pregnancy (as stated in many regulatory labels).
Age-related eligibility rules: Safety and effectiveness are not established in children below 12 years of age and in older adults 65 years and above.

Eligibility-Related Restrictions

  • Skin Condition: The product must not be applied to cuts, abrasions, eczematous skin, or sunburned skin.
  • Sun/UV Exposure: Exposure to sunlight and UV light must be minimized during use. Sunscreen and protective clothing are recommended when sun exposure cannot be avoided.
  • Lactation: Use during breastfeeding is generally allowed with caution; however, application to the chest area (nipple and areola) must be avoided to prevent infant exposure.
  • Hair Removal: Wax epilation (waxing) should not be performed on skin treated with the retinoid component.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for adapalene (the active ingredient in Deriva) is primarily focused on local dermal effects due to its minimal systemic absorption. The main constraints involve avoiding cumulative skin irritation and mitigating the risk of photosensitivity.


Documented Topical and Environmental Interactions

Interaction Domain Practical Implication
Other Topical Irritants Concurrent use with abrasive soaps, strong drying agents, astringents, or products containing high concentrations of alcohol, sulfur, resorcinol, or salicylic acid increases the risk of severe skin irritation. The use of certain topical medications (e.g., benzoyl peroxide) may require application at different times of the day to lessen irritation.
UV Radiation and Photosensitizing Agents Exposure to excessive sunlight, sunlamps, or tanning beds must be minimized during treatment. Caution is advised when using other medications known to increase sensitivity to light, such as certain antibiotics (e.g., fluoroquinolones) or diuretics (e.g., thiazides), due to the additive risk of photosensitivity.
Skin Procedures Irritating cosmetic procedures, including waxing, chemical hair depilatories, electrolysis, and permanent wave solutions, should be avoided on the treated areas to prevent heightened local adverse reactions.

These interaction parameters are based on official regulatory documentation and serve to guide appropriate management of the skin during therapy. No clinically significant systemic drug-drug interactions have been documented for this topical formulation.

Mechanism of Action

The action of Adapalene (Deriva) is defined by its ability to engage two fundamental and interconnected pharmacological domains at the cellular level, leading to the modulation of physiological processes related to epidermal differentiation.

Nuclear Receptor Agonism and Corrected Cell Growth

Adapalene acts as a selective agonist for nuclear Retinoic Acid Receptor-gamma ( RAR-gamma), the predominant regulator of skin cell differentiation. By modulating the gene expression governed by this receptor, the mechanism modulates keratinocyte growth and decreases corneocyte cohesion. This action contributes to the resolution of follicular obstruction.

Innate Immune Modulation and Inflammatory Suppression

Adapalene actively inhibits the Activator Protein 1 ( AP-1) transcription factor and down-regulates the Toll-Like Receptor 2 ( TLR-2), both central components of the innate immune signaling cascade. By suppressing these factors, the mechanism decreases the production of inflammatory mediators, contributing to a decreased local immune response and attenuated vascular permeability.

Dosage and Administration Information

How to Use Deriva

This section outlines the usage principles for Deriva (Adapalene) for its topical use.


Administration and Dosage Regimen

Feature Guideline
Route of Administration Topical (Cutaneous) application only.
Dosing Schedule Apply a small (pea-sized) amount as a thin film to the entire affected area.
Frequency The medicine is applied once daily, typically in the evening or before bedtime.

Procedural and Population Constraints

The application of Adapalene is a continuous regimen, usually requiring 8 to 12 weeks of daily use before the full effects are observed. The administration protocol requires the skin to be clean and dry prior to application. It must be applied only to the skin and contact with the eyes, lips, corners of the nose, and mucous membranes should be avoided.

Deriva is authorized for use in pediatric patients 12 years of age and older. The safety and efficacy of the product have not been established for patients under 12 or for those in the geriatric population (65 years and older). If a dose is missed, resume the product at the next scheduled time without applying a double amount.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Deriva


The information presented here summarizes the structure of the clinical research for Adapalene (the active ingredient in Deriva), focusing only on the research conducted for the indication of Acne Vulgaris as reported in regulatory and peer-reviewed sources. It is an overview of what researchers have explored, not a guide for treatment or a summary of individual outcomes.

Evidence from Clinical Studies for Acne Vulgaris

The evidence base for Adapalene was studied for Acne Vulgaris primarily using Randomized Controlled Trials (RCTs). These are the most rigorous type of study, where participants are randomly assigned to receive either the active preparation or an inactive product (vehicle). This design is used in research exploring how symptoms change over time and is the research type often relied upon during regulatory assessment.

The evidence base for Adapalene includes multiple comparative studies (RCTs) and systematic reviews. The research contributes to the broader evidence landscape used during regulatory assessment. The studies was evaluated in settings involving patients with conditions characterized by fluctuating or episodic manifestations of acne.

Study Focus: Measuring Changes in Acne Lesions

In the key clinical trials, researchers aimed to quantify changes in the physical manifestations of acne. The studies examined two main outcomes describing symptom intensity or variability and overall skin status.

Specifically, the studies report how symptoms evolved in the observed populations by counting both non-inflammatory lesions (like blackheads and whiteheads) and inflammatory lesions (such as papules and pustules). The findings describe patterns observed in the studies regarding these measured outcomes over the study period, typically lasting 8 to 12 weeks. This approach provides insight into short-term changes under specific clinical conditions.

Understanding Long-Term and Maintenance Evidence

Since acne is a condition where symptoms may vary in intensity and often recur, research has also explored the need for ongoing application, known as maintenance therapy. These studies was studied for periods longer than the initial treatment phase, commonly extending the observation up to 6 months (24 weeks), with research exploring patterns in extended application. The research explored patterns of change during the extended application periods. While some open-label studies monitored participants for up to a year, the most robust, placebo-controlled data is often associated with the 6-month observation period.

Key Studies & References

  1. Adapalene Topical Drug Information (MedlinePlus)

Frequently Asked Questions (FAQ)

Common questions about Deriva (FAQ)

Q: What is the best way to apply the Deriva product?

Regulatory documents state that Deriva is applied as a thin film to the entire affected area of the skin once daily. Product information also indicates that the skin should be gently washed and dried beforehand. Official guidance indicates that contact should be avoided with the eyes, lips, corners of the nose, and mucous membranes.

Q: Should I stop using my Deriva if I experience irritation, dryness, or peeling in the first week?

Official product information indicates that local skin reactions, such as redness, dryness, and peeling, are common during the initial weeks of treatment and usually lessen with continued use. If local skin reactions become severe or persist, official documents suggest temporary discontinuation or complete cessation may be considered.

Q: Is it necessary to apply a moisturizer before or after using Deriva?

Product information states that the skin should be clean and dry prior to application. Regulatory guidance suggests that a moisturizer may be used to help relieve dry skin or irritation that can occur during treatment. Non-comedogenic products are often recommended.

Q: Can I use Deriva if I am also using benzoyl peroxide for my acne?

Official information notes that using Deriva alongside other irritating topical products, such as those containing benzoyl peroxide, may increase the potential for skin irritation. Regulatory guidance indicates that application at different times of the day may be necessary to manage potential additive irritant effects.

Q: Is there a specific time of day that is better for applying this product?

The official product label indicates that the medication is applied once daily, typically in the evening.

Q: What is the specific concentration of Adapalene in the Deriva product?

The active ingredient, Adapalene, is available in various concentrations in topical formulations, such as 0.1% or 0.3%. The specific strength of Adapalene in a product can be verified on its packaging or in the official labeling documents.

Q: I've heard of other retinoids like tretinoin. Is Deriva (Adapalene) considered a first, second, or third-generation retinoid?

Official documents classify Adapalene as a retinoid-like compound. This classification is based on its mechanism as a selective nuclear Retinoic Acid Receptor-gamma ( RAR-gamma) agonist, which modulates cellular differentiation.

Q: Can I apply makeup or cosmetics over the area where I've applied the Deriva?

Regulatory patient information states that if cosmetics are used on the treated area, they should be non-comedogenic and non-astringent. The use of products that may cause drying or irritation is advised against, as this can contribute to additive local effects.

Q: If I am planning to become pregnant, do I need to stop using Deriva?

Official product information states that the product is contraindicated for women who are pregnant or planning a pregnancy. Use of the product should be discontinued before conception.

Q: Which specific type of acne lesions (like blackheads, whiteheads, or inflammatory spots) did the clinical trials measure?

Clinical trials measured the changes in two main categories of acne lesions. Studies examined both non-inflammatory lesions, which include blackheads (open comedones) and whiteheads (closed comedones), and inflammatory lesions, such as papules and pustules.

How should Deriva be stored and disposed of?

How to Store and Dispose of Deriva? — Official Regulatory Requirements

Storage and disposal instructions for Deriva are strictly governed by regulatory bodies to maintain the product's integrity and ensure safety.

Storage Requirements

Condition Official Requirement
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Do not freeze and protect from excessive heat.
Protection Keep the container tightly closed and protect from light. For certain formulations, keep away from open flames and sources of ignition.
Access The product must be stored out of the reach of children.

Disposal Requirements

Do not use the medicine after its expiry date has passed. Official regulations instruct users to return any unused or expired product to a pharmacist or follow established local drug take-back programs for safe disposal, ensuring compliance with environmental rules.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Deriva found in:

A-Z Index: